Your browser doesn't support javascript.
loading
CD40 and CD80/86 signaling in cDC1s mediate effective neoantigen vaccination and generation of antigen-specific CX3CR1+ CD8+ T cells.
Yamauchi, Takayoshi; Hoki, Toshifumi; Oba, Takaaki; Kajihara, Ryutaro; Attwood, Kristopher; Cao, Xuefang; Ito, Fumito.
Afiliação
  • Yamauchi T; Center for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
  • Hoki T; Center for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
  • Oba T; Center for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
  • Kajihara R; Center for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
  • Attwood K; Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.
  • Cao X; Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Ito F; Center for Immunotherapy, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. fumito.ito@roswellpark.org.
Cancer Immunol Immunother ; 71(1): 137-151, 2022 Jan.
Article em En | MEDLINE | ID: mdl-34037810
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Células Dendríticas / Antígeno B7-1 / Linfócitos T CD8-Positivos / Antígenos CD40 / Receptor 1 de Quimiocina CX3C Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Células Dendríticas / Antígeno B7-1 / Linfócitos T CD8-Positivos / Antígenos CD40 / Receptor 1 de Quimiocina CX3C Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Ano de publicação: 2022 Tipo de documento: Article